FDA v. R. J. Reynolds Vapor Co.

Docket Number: 23-1187
Citation: 606/1
Term: October Term 2024
Argued: January 21, 2025
Decided: June 20, 2025
Lower Court: United States Court of Appeals for the Fifth Circuit
Author: Associate Justice Amy Coney Barrett
Concurring: John G. Roberts, Jr., Clarence Thomas, Samuel A. Alito, Jr., Elena Kagan, Neil M. Gorsuch, Brett M. Kavanaugh
Dissenting: Ketanji Brown Jackson, Sonia Sotomayor

Read the official slip opinion (PDF)

AI-Generated Summary

Summary of Food and Drug Administration et al. v. R. J. Reynolds Vapor Co. et al.

1. Case Information:

Case Name: Food and Drug Administration et al. v. R. J. Reynolds Vapor Co. et al.
Docket Number: 23–1187
Dates: Argued January 21, 2025; Decided June 20, 2025
Lower Court: United States Court of Appeals for the Fifth Circuit

2. Facts of the Case:

The Family Smoking Prevention and Tobacco Control Act (TCA) mandates that manufacturers obtain Food and Drug Administration (FDA) approval before marketing new tobacco products. In 2016, the FDA classified e-cigarettes as new tobacco products under the TCA, but deferred enforcement to allow manufacturers time to seek approval. R. J. Reynolds Vapor Co. (RJR Vapor), a manufacturer of e-cigarettes including the Vuse Alto products, applied for FDA approval, which was denied on the grounds that marketing these products was not "appropriate for the protection of the public health."
RJR Vapor, based in North Carolina, partnered with a Texas-based retailer (Avail Vapor Texas, L.L.C.) and a Mississippi-based trade association to file a joint petition for judicial review in the Fifth Circuit, leveraging the retailers’ locations for venue. The FDA challenged the venue, arguing that only the applicant (RJR Vapor) was "adversely affected" under the TCA and thus eligible to seek review, limiting venue to the D. C. Circuit or Fourth Circuit. A divided Fifth Circuit panel upheld the venue as proper, prompting the FDA to seek Supreme Court review.

3. Legal Issues Presented:

The central question was whether retailers, who would sell a new tobacco product but for the FDA’s denial of a manufacturer’s application, are "adversely affected" under 21 U.S.C. §387l(a)(1) of the TCA and thus have the right to seek judicial review.
The case involves statutory interpretation of the TCA, specifically the meaning of "any person adversely affected," and whether it extends beyond the applicant manufacturer to include retailers.
The FDA argued that only the applicant manufacturer is within the TCA’s zone of interests and thus eligible for review, while RJR Vapor and the retailers contended that the broad language of "any person adversely affected" includes retailers who suffer economic harm from the denial.

4. The Court's Decision (Main Opinion):

Author & Type: Justice Barrett delivered the opinion of the Court, representing a Majority opinion, joined by Chief Justice Roberts and Justices Thomas, Alito, Kagan, Gorsuch, and Kavanaugh.
Holding: Retailers who would sell a new tobacco product if not for the FDA’s denial order are "adversely affected" under §387l(a)(1) of the TCA and may seek judicial review.
Legal Reasoning: The Court applied the "zone of interests" test to determine if retailers fall within the class of persons the TCA grants a right to sue. Drawing on precedent from the Administrative Procedure Act (APA) and other statutes, the Court interpreted "adversely affected" broadly, encompassing anyone "arguably within the zone of interests" protected by the statute. The Court rejected the FDA’s argument that only the applicant manufacturer is aggrieved, noting the TCA’s use of "any person" suggests multiple parties can be affected. Retailers face direct economic harm and potential sanctions from a denial, placing them within the statute’s protective scope. The Court also contrasted the TCA’s broader language for denial challenges with narrower language elsewhere in the statute for withdrawal challenges, reinforcing a presumption of broader applicability. Structurally, the Court found no basis in the TCA’s text to limit judicial review to manufacturers.
Disposition: The Fifth Circuit’s denial of the FDA’s motion to dismiss or transfer for lack of venue was affirmed, and the case was remanded for further proceedings.

5. Concurring Opinion(s) (if any):

There are no concurring opinions mentioned in the provided text.

6. Dissenting Opinion(s) (if any):

Justice(s): Justice Jackson, joined by Justice Sotomayor, filed a dissenting opinion.
Reasons for Dissent: The dissent argued that the majority misapplied the zone-of-interests test by focusing on the broad language of the judicial review provision (§387l(a)(1)) rather than the specific statutory scheme for marketing approvals under §387j(c). Justice Jackson contended that the TCA’s premarketing approval process exclusively involves manufacturers and the FDA, with no role or procedural rights for retailers, indicating Congress did not intend to protect retailers’ interests. The dissent highlighted that retailers lack reliance interests at the denial stage, unlike manufacturers, and pointed to the TCA’s specific limitation of challenges to withdrawal orders to application holders as evidence of Congress’s intent to exclude retailers. Additionally, the dissent expressed concern that allowing retailers to sue enables manufacturers to circumvent venue restrictions, undermining the statutory framework. The dissent urged a narrower interpretation aligned with congressional intent, analogizing to precedents like Block v. Community Nutrition Institute, which limited judicial review based on statutory structure.

7. Potential Significance:

The ruling establishes a precedent that broadens the scope of who can challenge FDA denials under the TCA, potentially allowing a wider range of parties, such as retailers, to seek judicial review in future cases involving new tobacco products. This interpretation may influence how "adversely affected" is construed in other statutory contexts, reinforcing a presumption of expansive access to judicial review unless explicitly limited by Congress. Additionally, by affirming the retailers’ right to petition in the Fifth Circuit, the decision could impact venue strategies in administrative law challenges, potentially encouraging joint petitions to access favorable circuits, though the Court declined to address whether each petitioner in a joint petition must independently establish venue.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Key terms: E-Cigarettes, FDA Approval, Judicial Review